The simple truth of the matter is that the Pharmaceutical Industry is going to have a rather drastic slide. The fact is that there is a disease that is killing white blood cells. As the disease grows, the source for new antibodies subsequently declines. They are inversely correlated (rate of disease vs rate of new antibodies). As a result there will be a drop in earnings forecasts, which will make it harder to raise money for the pharmaceutical companies. This risk was not mentioned in the 10K of the following company.

It is as if they do not know that the solution is theoretically The KIN Intravenous Solution (Glucose + Cloned White Blood Cells). If anybody needs more information on the protocols for ex vivo production of white blood cells, then please contact the Chairman at khalidnatto@gmail.com.

Chairman's Research on "Merck & Co., Inc." (MRK)

Merck & Co.,Inc. (MRK)

Merck & Co., Inc. Graph source Edgar Online Pro on April 19th, 2006

The Following data is sourced from Yahoo Finance & the ANNUAL REPORT ON FORM 10-K For the Year Ended December 31, 2005 . The overview of the company was:

Overview:

Merck & Co., Inc. , a pharmaceutical company, engages in the discovery, development, manufacture, and marketing of various products for human and animal health. The company’s products consist of therapeutic and preventive agents sold by prescription for the treatment and prevention of human disorders. It offers Zocor, a atherosclerosis product; Cozaar, Hyzaar, and Vasotec, which are hypertension/heart failure products; Fosamax, an osteoporosis product used for the treatment and prevention of osteoporosis; Singulair, a respiratory product and a leukotriene receptor antagonist used for the treatment of asthma and for relief of symptoms of seasonal allergic rhinitis; Varivax, a live virus vaccine of chickenpox; M-M-R II, a pediatric vaccine for the prevention of measles, mumps, and rubella; Pneumovax, a vaccine for the prevention of pneumococcal disease; Recombivax HB, a vaccine for the prevention of hepatitis B; Primaxin and Cancidas, which are antibacterial/antifungal products; Proscar, a urology product used for treatment of symptomatic benign prostate enlargement; Cosopt and Trusopt, which are ophthalmological products; Maxalt, which is used for the treatment of acute migraine; and Propecia, which is used for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, and managed health care providers, such as health maintenance organizations and other institutions through its professional representatives. Merck & Co. has a collaboration agreement with NicOx SA to develop antihypertensive drugs using NicOx's proprietary nitric oxide-donating technology. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

Risk Factors (sourced from 10 k form please research them for further detail):

1. The Company faces significant litigation related to Vioxx.

2. Certain of the Company’s major products are going to lose patent protection in the near future and, when that occurs, the Company expects a significant decline in sales of those products.

3. The Company’s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that have lost patent protection.

4. The Company’s products, including products in development, can not be marketed unless the Company obtains and maintains regulatory approval.

5. The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business would be adversely affected.

6. The Company faces intense competition from lower-cost generic products.

7. The Company faces intense competition from new products.

8. Cautionary Factors that May Affect Future Results (See 10 K Form)

Recent articles on the medical industry:

For New Research Projects Contact The Chairman at Email: khalidnatto@gmail.com

First name:

Last name:

Email address:

Company:

Address 1:

Address 2:

City:

State:

Zip code:

Phone:

Request information on product?

Topic

===================================================================

Disclaimer of Warranty and Limitation of LiabilityThe information,
products and services on this web site or letter are provided on an "AS IS," "WHERE IS" and "WHERE AVAILABLE" basis.
The KIN Consortium does not warrant the information or services provided herein or your use of this
web site generally, either expressly or impliedly, for any particular purpose and expressly disclaims any implied warranties,
including but not limited to, warranties of title, non-infringement, merchantability or fitness for a particular purpose.
The KIN Consortium will not be responsible for any loss or damage that could result from interception
by third parties of any information or services made available to you via this web site. Although the information provided
to you on this web site is obtained or compiled from sources we believe to be reliable, The KIN Consortium
cannot and does not guarantee the accuracy, validity, timeliness or completeness of any information or data made available
to you for any particular purpose. Neither The KIN Consortium , nor any of its affiliates, directors,
officers or employees, nor any third party vendor, will be liable or have any responsibility of any kind for any loss or damage
that you incur in the event of any failure or interruption of this web site, or resulting from the act or omission of any
other party involved in making this web site, the data contained herein or the products or services offered on this web site
available to you, or from any other cause relating to your access to, inability to access, or use of the web site or these
materials, whether or not the circumstances giving rise to such cause may have been within the control of The KIN
Consortium or of any vendor providing software or services. In no event will The KIN Consortium
or any such parties be liable to you, whether in contract or tort, for any direct, special, indirect, consequential or incidental
damages or any other damages of any kind even if The KIN Consortium or any other such party has been
advised of the possibility thereof. This limitation on liability includes, but is not limited to, the transmission of any
viruses which may infect a user's equipment, failure of mechanical or electronic equipment or communication lines, telephone
or other interconnect problems (e.g., you cannot access your internet service provider), unauthorized access, theft, operator
errors, strikes or other labor problems. The KIN Consortium cannot and does not guarantee continuous,
uninterrupted or secure access to the web site.

Proprietary RightsAll right, title and interest
in this web site and any content contained herein is the exclusive property of The KIN Consortium ,
except as otherwise stated. Unless otherwise specified, this web site is for your personal and non-commercial use only and
you may print, copy and download any information or portion of this web site for your personal use only. You may not modify,
copy, distribute, transmit, display, perform, reproduce, publish, license, frame, create derivative works from, transfer,
or otherwise use in any other way for commercial or public purposes in whole or in part any information, software, products
or services obtained from this web site, except for the purposes expressly provided herein, without The KIN Consortium's prior
written approval. If you copy or download any information or software from this web site, you agree that you will not remove
or obscure any copyright or other notices or legends contained in any such information.

The KIN Consortium and
other trademarks and service marks referenced herein are trademarks and service marks of The KIN Consortium .
The names of other companies and third-party products or services mentioned herein may be the trademarks or service marks
of their respective owners. You are prohibited from using any marks for any purpose including, but not limited to use as metatags
on other pages or sites on the World Wide Web without the written permission of The KIN Consortium
or such third party, which may own the marks.

Pursuant to Section 512(c)(2) of the Copyright Act, The KIN
Consortium designates the following agent to receive notifications of claimed infringement: Khalid I Natto,
The KIN Consortium , Email: kalnatto2000@yahoo.com, Website: http://khalidnatto.tripod.com

Use of LinksThis web site contains links
to third party web sites. These links are provided only as a convenience. The inclusion of any link is not and does not imply
an affiliation, sponsorship, endorsement, approval, investigation, verification or monitoring by The KIN Consortium
of any information contained in any third party web site. In no event shall The KIN Consortium be responsible
for the information contained on that site or your use of or inability to use such site. You should also be aware that the
terms and conditions of such site and the site's privacy policy may be different from those applicable to your use of this
web site.